摘要
抗体-毒素融合剂或免疫毒素,是一类新型的细胞毒性药物,由细菌或植物毒素组成,这些毒素与单克隆抗体或特定的生长因子连接在一起。然而,由于毛细血管渗漏综合征(CLS)是一种严重的免疫激发的、危及生命的副作用,导致内皮损伤,导致液体从血液中逃逸到肺、肌肉和脑等组织,发展器官衰竭,最终导致死亡,因此在临床上获得完全的效力受到限制。其潜在机制包括对内皮细胞的直接损伤、急性炎症、淋巴细胞活化杀伤(LAK)细胞的参与、细胞/细胞基质连接性的改变和细胞骨架功能障碍。肿瘤部位生物分布极差,外溢模式不均匀,导致肿瘤组织中邻近内皮细胞逐渐释放和启动,促炎性细胞因子的分泌,急性炎症的发展和淋巴因子激活杀伤细胞(LAK)的参与。应用毒素的固有免疫原性是CLS发病的另一个重要决定因素。具有较强内在免疫原性的毒素具有更大的发生CLS的可能性。近年来,具有保守细胞毒性的新一代抗体和突变毒素的开发,部分降低了CLS发展的风险。在此,我们描述了CLS的可能机制,并介绍了一些最近应用的尽可能减少CLS发病率的策略。
关键词: 血管渗漏综合征,免疫原性,细胞因子,免疫毒素,结合侧屏障,淋巴运动激活的杀伤细胞。
Current Molecular Medicine
Title:Probable Mechanisms Involved in Immunotoxin Mediated Capillary Leak Syndrome (CLS) and Recently Developed Countering Strategies
Volume: 18 Issue: 5
关键词: 血管渗漏综合征,免疫原性,细胞因子,免疫毒素,结合侧屏障,淋巴运动激活的杀伤细胞。
摘要: Antibody-toxin fused agents or immunotoxins, are a newly engineered class of cytotoxic agents consisting of a bacterial or plant toxin moiety hooked up either to a monoclonal antibody or a specific growth factor. Nevertheless, acquiring a full potency in clinic is mostly restricted due to the Capillary leak syndrome (CLS), a serious immune provoked, life-threatening side effect, subsequent to the endothelial damage, resulting in fluid escape from the bloodstream into tissues including lungs, muscle and brain, developing organ failure and eventually death. Proposed underlying mechanisms include direct damage to endothelial cells, acute inflammation, Lymphokine-activated killer (LAK) cells engagement, alteration in cell-cell/cell-matrix connectivities and cytoskeletal dysfunction. Very poor biodistribution and heterogeneous extravasation pattern in tumor site result in accumulation of ITs close to the extravasation site, gradual toxin release and initiation of nearby endothelial cells lysis, secretion of pro-inflammatory cytokines, development of acute inflammation and engagement of Lymphokine-activated killer (LAK) cells. Intrinsic immunogenicity of applied toxin moiety is another important determinant of CLS incidence. Toxins with more intrinsic immunogenicity possess more probability for CLS development. Recently, development of new generations of antibodies and mutated toxins with conserved cytotoxicity has partly tapered risk of CLS development. Here, we describe probable mechanisms involved in CLS and introduce some of the recently applied strategies for lessening incidence of CLS as much as possible.
Export Options
About this article
Cite this article as:
Probable Mechanisms Involved in Immunotoxin Mediated Capillary Leak Syndrome (CLS) and Recently Developed Countering Strategies, Current Molecular Medicine 2018; 18 (5) . https://dx.doi.org/10.2174/1566524018666181004120112
DOI https://dx.doi.org/10.2174/1566524018666181004120112 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sol-gel Encapsulation of Biomolecules and Cells for Medicinal Applications
Current Topics in Medicinal Chemistry Pivotal Role of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Inflammatory Pulmonary Diseases
Current Protein & Peptide Science MicroRNA Targeting as a Therapeutic Strategy Against Glioma
Current Molecular Medicine Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology Tetracyclines and Pulmonary Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial: [Hot Topic: Central Nervous System Drugs in the Treatment of Neurological Disorders]
Central Nervous System Agents in Medicinal Chemistry Why and how do Microbubbles Enhance the Effectiveness of Diagnostic and Therapeutic Interventions in Cerebrovascular Disease?
Current Pharmaceutical Design Coated with Nanomaterials Intraocular Lenses, Ophthalmic and Human Body Implantable Devices with High Catalytic Antioxidant Activities: A New Nanotechnology Strategy of Peroxidase Cellular Enzyme Mimics Increasing the Biocompatibility and Therapeutic Deployment of the Medical Prosthetic Device
Recent Patents on Drug Delivery & Formulation Biomarker-Detection Technologies for Comprehensive Medical Diagnosis During Deep-Space Missions
Recent Patents on Space Technology Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis
Recent Patents on Biomedical Engineering (Discontinued) Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Current Topics in Medicinal Chemistry Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology Therapy Against Ischemic Injury
Current Pharmaceutical Design Exogenous Surfactant in Paediatric Acute Lung Injury and Acute Respiratory Distress Syndrome
Current Drug Safety Nitric Oxide and Disorders of the Erythrocyte: Emerging Roles and Therapeutic Targets
Cardiovascular & Hematological Disorders-Drug Targets Colchicine: An Ancient Drug with Multiple Benefits
Current Pharmaceutical Design Dengue Fever: Theories of Immunopathogenesis and Challenges for Vaccination
Inflammation & Allergy - Drug Targets (Discontinued) From Brain Ischemia-Reperfusion Injury to Possible Sporadic Alzheimers Disease
Current Neurovascular Research Periodontitis and Redox Status: A Review
Current Pharmaceutical Design